Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies

Abstract Background Navafenterol (AZD8871) is a novel, long-acting, dual-pharmacology (muscarinic receptor antagonist and β2−adrenoceptor agonist) molecule in development for chronic obstructive pulmonary disease and asthma. Methods These two phase I, randomised, single-blind, multiple-ascending-dos...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Victor Balaguer, Muna Albayaty, Eulalia Jimenez, Ulrika Wählby-Hamrén, Carol Astbury, Beatriz Seoane, Marie-Pierre Malice, Alejhandra Lei, Ajay Aggarwal, Ioannis Psallidas
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2020-09-01
Colecção:Respiratory Research
Assuntos:
Bronchodilator
COPD
MABA
Dual-pharmacology muscarinic receptor antagonist β2-adrenoceptor agonist
Safety
Pharmacokinetics
Acesso em linha:http://link.springer.com/article/10.1186/s12931-020-01474-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados